Navigation Links
Alzheimer's Pilot Study Proposed for Ustekinumab (Stelara)
Date:6/12/2013

(PRWEB) June 12, 2013

Currently clinical trials are ongoing in the U.S., Nicaragua and U.K. to evaluate the efficacy of the FDA approved psoriasis drug Enbrel as an Alzheimer's treatment.* Similar clinical trials are needed to evaluate the efficacy of the FDA approved psoriasis drug Stelara as an Alzheimer's treatment. Both Enbrel and Stelara work by blocking molecular sub-units of inflammatory protiens. Enbrel targets TNF-alpha, Stelara targets IL-12 and IL-23.

Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from Alzheimer's since 2010 by teaching perispinal Enbrel injection technique to physicians and caregivers.

Neurological Wellness Center offers a complete two-hour course on Alzheimer's treatment covering all aspects of perispinal injection technique at their center in Managua Nicaragua.

"Although there is a wide range of outcomes, the observed results and anecdotal reports we have received from physicians and caregivers treating individuals with Alzheimer's with perispinally administered Enbrel, generally confirm the findings of Edward Tobinick M.D," (.ncbi.nlm.nih.gov/pmc/articles/PMC1785182/ ) stated Rolando Hernandez M.D., neurosurgeon for Neurological Wellness Center.

For many, flying to Neurological Wellness Center in Managua Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 37-page e-book are now available online at: neurological-recovery-guide.com.

Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.

Neurological Wellness Center’s perispinal Enbrel is effective as an Alzheimer's treatment, stroke treatment with our stroke clinical trial and as a TBI treatment.

The drug Enbrel is available now. Enbrel received FDA approval in 1998. Its safety profile is well understood. For Enbrel to effectively treat Alzheimer’s, stroke and TBI, it must be administered to the back of the neck precisely between the cervical vertebrae C-5 and C-6. This perispinal injection allows Enbrel to enter the brain by lymph drainage assisted by gravity. Fortunately for the millions of people now afflicted with Alzheimer’s, stroke and TBI, a video is now available online detailing in step-by-step fashion how to administer a perispinal injection of Enbrel,” said Dr. Rolando Hernandez.

To enroll in a hands-on instructional course on perispinal injections visit: reversealzheimersnow.com.

To purchase an instructional video and e-book on administering perispinal injections visit: neurological-recovery-guide.com

*://clinicaltrials.gov/ct2/show/NCT01716637?term=etanercept+AND+brain&rank=1
:prweb.com/releases/2013/5/prweb10603523.htm
://clinicaltrials.gov/show/NCT01068353

Read the full story at http://www.prweb.com/releases/2013/6/prweb10702340.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Two Leading Alzheimer's Disease Researchers Recognized with MetLife Foundation Awards
2. myCNAjobs Delivers Alzheimer's and Memory Caregiver Training Online
3. BMA Affordable Assisted Living Community to Host Educational Program on Alzheimer's Disease
4. Alzheimer's Treatment Clinical Trial Receives Clearance
5. New Study Links Air Pollution to Alzheimer’s Disease -- Says Cure Alzheimer's Fund
6. Life Extension Foundation Seeks Volunteers with Alzheimer's to Participate in a Clinical Trial Utilizing a Common Arthritis Drug
7. Congresswoman Michelle Bachmann Supports Barak Obama's Call to Prioritize Research to "Unlock the Answers to Alzheimer's"
8. Watson, IBM'S Supercomputer is Now Programmed to Recommend Perispinally Administered Etanercept as an Alzheimer's Disease Treatment
9. Goldberg & Goldberg Files Wrongful Death Lawsuit on Behalf of a 91 year-old Alzheimer's Patient Who Froze to Death Outside a Retirement Community
10. A Feinstein Institute for Medical Research Study Shows Early Cognitive Problems among Those Who Eventually Get Alzheimer's
11. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology: